136 related articles for article (PubMed ID: 22978343)
41. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
[TBL] [Abstract][Full Text] [Related]
42. Population study of dihydropyrimidine dehydrogenase in cancer patients.
Etienne MC; Lagrange JL; Dassonville O; Fleming R; Thyss A; Renée N; Schneider M; Demard F; Milano G
J Clin Oncol; 1994 Nov; 12(11):2248-53. PubMed ID: 7964939
[TBL] [Abstract][Full Text] [Related]
43. Local Irradiation Modulates the Pharmacokinetics of Metabolites in 5-Fluorouracil-Radiotherapy-Pharmacokinetics Phenomenon.
Liu JH; Tsai TH; Chen YJ; Wang LY; Liu HY; Hsieh CH
Front Pharmacol; 2020; 11():141. PubMed ID: 32174836
[TBL] [Abstract][Full Text] [Related]
44. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
[TBL] [Abstract][Full Text] [Related]
45. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P
Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199
[TBL] [Abstract][Full Text] [Related]
46. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
Capitain O; Asevoaia A; Boisdron-Celle M; Poirier AL; Morel A; Gamelin E
Clin Colorectal Cancer; 2012 Dec; 11(4):263-7. PubMed ID: 22683364
[TBL] [Abstract][Full Text] [Related]
47. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Meropol NJ; Niedzwiecki D; Hollis D; Schilsky RL; Mayer RJ;
Cancer; 2001 Apr; 91(7):1256-63. PubMed ID: 11283924
[TBL] [Abstract][Full Text] [Related]
48. Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome.
Pohlen U; Rieger H; Kunick-Pohlen S; Berger G; Buhr HJ
Anticancer Res; 2007; 27(1B):667-74. PubMed ID: 17348458
[TBL] [Abstract][Full Text] [Related]
49. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients.
Casale F; Canaparo R; Serpe L; Muntoni E; Pepa CD; Costa M; Mairone L; Zara GP; Fornari G; Eandi M
Pharmacol Res; 2004 Aug; 50(2):173-9. PubMed ID: 15177306
[TBL] [Abstract][Full Text] [Related]
50. Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
Okabe S; Ishikawa T; Tanami H; Kuwabara H; Fukahara T; Udagawa M; Ootsukasa S; Arai T; Maruyama S; Murase N; Yamashita H; Iwai T
J Med Dent Sci; 2002 Jun; 49(2):77-84. PubMed ID: 12627817
[TBL] [Abstract][Full Text] [Related]
51. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
52. Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients.
Fang L; Jiang Y; Yang Y; Zheng Y; Zheng J; Jiang H; Zhang S; Lin L; Zheng J; Zhang S; Zhuang X
Oncotarget; 2016 Dec; 7(49):81880-81887. PubMed ID: 27636992
[TBL] [Abstract][Full Text] [Related]
53. [Population study of dihydropyrimidine dehydrogenase in cancer patients].
Etienne MC; Milano G; Renée N; Lagrange JL; Dassonville O; Thyss A; Schneider M; François E; Fleming R; Demard F
Bull Cancer; 1995 Sep; 82(9):705-10. PubMed ID: 8535028
[TBL] [Abstract][Full Text] [Related]
54. [Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance].
Etienne MC; Milano G; Fleming RA; Thyss A; Renée N; Schneider M; Demard F
Bull Cancer; 1992; 79(12):1159-63. PubMed ID: 1304835
[TBL] [Abstract][Full Text] [Related]
55. How can we best monitor 5-FU administration to maximize benefit to risk ratio?
Goirand F; Lemaitre F; Launay M; Tron C; Chatelut E; Boyer JC; Bardou M; Schmitt A
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1303-1313. PubMed ID: 30451549
[TBL] [Abstract][Full Text] [Related]
56. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
57. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
[TBL] [Abstract][Full Text] [Related]
58. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
59. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
[TBL] [Abstract][Full Text] [Related]
60. Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Calvo E; Cortés J; González-Cao M; Rodríguez J; Aramendía JM; Fernández-Hidalgo O; Martín-Algarra S; Salgado JE; Martínez-Monge R; de Irala J; Brugarolas A
Oncology; 2002; 63(3):254-65. PubMed ID: 12381905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]